Seeking Alpha

Isis Pharmaceuticals (ISIS +0.1%) plans to start Phase II trials of its STAT3RX treatment in...

Isis Pharmaceuticals (ISIS +0.1%) plans to start Phase II trials of its STAT3RX treatment in patients with advanced cancer after "impressive" preliminary data in a Phase I study. The early results suggest that the "drug can produce responses in patients with advanced cancer who have failed to respond to other therapies," says David Hong of the University of Texas. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector